相关实验视频

Updated: Jun 23, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

埃达拉德克斯本醇对急性缺血性中风患者的功能结果和炎症反应的影响

Wenxia Chen¹, Hanqing Zhang², Zhenzhen Li¹

¹Department of Neurology, Nanjing First Hospital, Nanjing Medical University, No.68 Changle Road, Nanjing, 210006, China.

|June 20, 2024

概括

埃达拉德克斯本醇改善了急性缺血性中风 (AIS) 患者的功能结果. 这种神经保护剂降低了促炎性细胞因子,并增强了抗炎性标记物,有助于恢复.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

急性缺血性中风 (AIS) 给健康带来了重大挑战.
埃达拉德克斯本醇因其神经保护性质而闻名.
研究其对AIS功能结果和炎症的影响至关重要.

研究的目的:

评估EDARAVONE DEXBORNOL在改善AIS患者功能结局方面的疗效.
评估埃达拉德克斯波内尔对AIS系统性炎症反应的影响.

主要方法:

从AISRNA研究 (NCT04175691) 中招募AIS患者.
分成两组:一组在中风发作后48小时内接受埃达拉 (edaravone dexborneol) (37.5 mg/12小时,静脉注射),另一组为对照组.
测量细胞因子水平 (IL-1β,IL-6,IL-17,IL-4,IL-10,等等) 的测量在中风发作后的14天内.

主要成果:

埃达拉德克斯波内尔治疗组显示,修改的兰金尺度得分<2的比例显著更高 (70.7%与47.8%相比).
用埃达拉德克斯本醇治疗的患者表现出IL-1β,IL-6和IL-17的表达较低.
在治疗组中观察到较高的IL-4和IL-10表达水平.

结论:

埃达拉德克斯本醇在AIS后90天显著改善功能结果.
治疗抑制了促炎性细胞因子表达.
埃达拉德克斯本醇增加了抗炎性细胞因子水平,有助于神经保护.

关键词:

急性缺血性中风是一次急性缺血性中风.埃达拉德克斯波诺醇 (edaravone dexborneol) 是一种可以使用的功能性的结果.炎症反应是一种炎症反应.介质蛋白是介质蛋白中的一种.修改的排名量表修改的排名量表

更多相关视频

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model

Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model

Published on: December 9, 2018

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...